Karyopharm Therapeutics Inc. (KPTI) released Loss for fourth quarter of -$30 million
The company's bottom line totaled -$30 million, or -$0.24 per share. This compares with -$41 million, or -$0.36 per share, last year.
The company's revenue for the period fell 9.1% to $30 million from $33 million last year.
Karyopharm Therapeutics Inc. earnings at a glance (GAAP) :
-Earnings: -$30 Mln. vs. -$41 Mln. last year.
-EPS: -$0.24 vs. -$0.36 last year.
-Revenue: $30 Mln vs. $33 Mln last year.
For comments and feedback: editorial@rttnews.com